Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

3.270 -0.180 (-5.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
A Preview Of Cellectis's Earnings
 
Via Benzinga
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
From Cellectis Inc.
Via GlobeNewswire
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
Cellectis Touts Positive Preliminary Data From Two Leukemia Trials
 
Via Benzinga
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
From Cellectis Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
From Cellectis Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Cellectis Announces Pricing of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Cellectis Announces Launch of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
From Cellectis Inc.
Via GlobeNewswire
Why Is Calyxt (CLXT) Stock Up 140% Today?
Calyxt (CLXT) stock is rocketing higher on Tuesday after the company signed an all-stock merger agreement with Cibus Global. 
Via InvestorPlace
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
From Cellectis Inc.
Via GlobeNewswire
5 Most Expensive Health Care Stocks You Should Worry About
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
Via Benzinga
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
From Cellectis Inc.
Via GlobeNewswire
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
From Cellectis Inc.
Via GlobeNewswire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
From Cellectis Inc.
Via GlobeNewswire
Cellectis's Earnings Outlook
Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Cellectis will... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.